Study #2014-0729
Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
Study Status
Open
Treatment Agent
Elotuzumab,Lenalidomide
Principal Investigator
Sheeba K. Thomas
Description
The goal of this clinical research study is to learn if the combination of elotuzumab and revlimid (also called lenalidomide) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (a transplant using your own stem cells). The safety of this drug combination will also be studied.
General Information
Disease Group: Myeloma
Treatment Agent: Elotuzumab,Lenalidomide
Treatment Location: Only at MDACC
Sponsor: Bristol-Myers Squibb
Study Status
IRB Review and Approval Date: 04/14/2015
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myeloma
Study phase:
Phase II
Physician name:
Sheeba K. Thomas
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789